Novogen up 13% premarket on positive brain cancer study results
Sounds promising. It hasn't been tried in humans yet but the key here is that it preferentially kills tumor cells over normal brain cells, at least in the test tube.
Posted on: 05/11/2015
- Nano cap Novogen (NASDAQ:NVGN) jumps 13% premarket on increased volume in response to its announcement that its experimental cancer drug candidate, TRXE-009, demonstrated the ability to kill cancer cells from pediatric patients with an incurable form of brain cancer called diffuse intrinsic pontine glioma (DIPG). Patients with DIPG have poor prognoses with a median survival of less than one year. Its diffuse nature precludes the use of surgery, radiation only provides temporary relief and chemotherapy shows no benefit.
- In patient-derived cell cultures, TRXE-009 killed DIPG cells at therapeutically relevant concentrations by inducing a type of programmed cell death calledcaspase-dependent apoptosis. Normal brain cells called astrocytes were only affected at much higher concentrations of TRXE-009 indicating an encouraging therapeutic index.
- The data were presented at the 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research in San Diego, May 7-8.
- TRXE-009 is a pan-acting anti-cancer cytotoxic molecule in a family called super-benzopyrans. Its precise mechanism of action is unknown but it induces cell death in cancer cells with stem cell-like activity.
Click HERE to return to brain tumor news headlines